Found: 17
Select item for more details and to access through your institution.
Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia.
- Published in:
- 2018
- By:
- Publication type:
- journal article
A narrative review on antimicrobial dosing in adult critically ill patients on extracorporeal membrane oxygenation.
- Published in:
- Critical Care, 2024, v. 28, n. 1, p. 1, doi. 10.1186/s13054-024-05101-z
- By:
- Publication type:
- Article
Immune Mechanisms in Myelodysplastic Syndrome.
- Published in:
- International Journal of Molecular Sciences, 2016, v. 17, n. 6, p. 944, doi. 10.3390/ijms17060944
- By:
- Publication type:
- Article
Extrapulmonary manifestations of severe acute respiratory syndrome coronavirus‐2 infection.
- Published in:
- Journal of Medical Virology, 2021, v. 93, n. 5, p. 2645, doi. 10.1002/jmv.26595
- By:
- Publication type:
- Article
Idiopathic erythrocytosis: A diagnostic and management challenge with emerging areas for exploration.
- Published in:
- British Journal of Haematology, 2024, v. 204, n. 3, p. 774, doi. 10.1111/bjh.19287
- By:
- Publication type:
- Article
Initiating a Standard Venous Thromboembolism Prophylaxis Order Set Designed to Improve Patient Outcomes at Los Angeles County+University of Southern California.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Pegylated interferon for the treatment of early myelofibrosis: correlation of serial laboratory studies with response to therapy.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Clinical and pathological features of clonal cytopenia of undetermined significance presenting with isolated thrombocytopenia (CCUS‐IT).
- Published in:
- 2024
- By:
- Publication type:
- Case Study
MPN-127: Add-On Parsaclisib (a PI3K5 Inhibitor) in Patients with Myelofibrosis and Suboptimal Response to Ruxolitinib: Interim Analysis from a Phase 2 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S354, doi. 10.1016/S2152-2650(21)01819-X
- By:
- Publication type:
- Article
Poster: MPN-127: Add-On Parsaclisib (a PI3Kδ Inhibitor) in Patients with Myelofibrosis and Suboptimal Response to Ruxolitinib: Interim Analysis from a Phase 2 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S232, doi. 10.1016/S2152-2650(21)01457-9
- By:
- Publication type:
- Article
Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients With Myelofibrosis: A Case Series.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Correction of refractory thrombocytopenia and anemia following withdrawal of extended release niacin.
- Published in:
- American Journal of Hematology, 2016, v. 91, n. 7, p. E318, doi. 10.1002/ajh.24371
- By:
- Publication type:
- Article
Treatment of Cancer‐Associated Venous Thromboembolism with Low‐Molecular‐Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats.
- Published in:
- Oncologist, 2021, v. 26, n. 1, p. e8, doi. 10.1002/onco.13584
- By:
- Publication type:
- Article
Emerging treatment options for myelofibrosis: focus on pacritinib.
- Published in:
- OncoTargets & Therapy, 2016, v. 9, p. 2655, doi. 10.2147/OTT.S93875
- By:
- Publication type:
- Article
A Retrospective Study of the Combination of Rituximab, Cyclophosphamide and Dexamethasone for the Treatment of Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia.
- Published in:
- Acta Haematologica, 2020, v. 143, n. 3, p. 244, doi. 10.1159/000501538
- By:
- Publication type:
- Article
Autoimmune Myelofibrosis: Clinical Features, Course, and Outcome.
- Published in:
- Acta Haematologica, 2017, v. 138, n. 3, p. 129, doi. 10.1159/000479103
- By:
- Publication type:
- Article
Therapeutic drug monitoring following crushed administration of delayed-release posaconazole tablets via enteral feeding tubes.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2023, v. 78, n. 2, p. 553, doi. 10.1093/jac/dkac427
- By:
- Publication type:
- Article